ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near London, England, GBR:

A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer

folate receptor alpha-expressing (5% or higher) platinum resistant ovarian cancerThe dose escalation part of the study will primari...

Enrolling
Advanced Ovarian Cancer
Platinum-resistant Ovarian Cancer
Drug: MOv18 IgE

Phase 1

Epsilogen Ltd

London, United Kingdom and 6 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

London, United Kingdom and 125 other locations

The goal of this clinical trial is to establish if THEO-260 is safe to administer to adult females with ovarian cancer. It will als ...

Enrolling
Ovarian Cancer
Biological: THEO-260

Phase 1, Phase 2

Theolytics Limited

London, United Kingdom

Locations recently updated

mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in...

Active, not recruiting
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Pegylated Liposomal Doxorubicin + SL-172154
Drug: Mirvetuximab + SL-172154

Phase 1

Shattuck Labs

London, London, city of, United Kingdom and 20 other locations

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

London, United Kingdom and 46 other locations

positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...

Active, not recruiting
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin

Phase 2

ImmunoGen
ImmunoGen

London, United Kingdom and 70 other locations

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Alpelisib
Drug: Pegylated liposomal doxorubicin (PLD)

Phase 3

Novartis
Novartis

London, United Kingdom and 92 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

London, United Kingdom and 176 other locations

phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be...

Enrolling
Ovarian Clear Cell Carcinoma
Ovarian Clear Cell Adenocarcinoma
Drug: NXP800

Phase 1

Nuvectis Pharma

London Borough of Sutton, Sutton Surrey, United Kingdom and 21 other locations

Locations recently updated

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

London, United Kingdom and 50 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems